{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:25:41Z","timestamp":1787775941980,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Single-photon emission computerized tomography for myocardial perfusion imaging (MPI) is a non-invasive technique. MPI is performed by subjecting the patient to exercise or by using a pharmacological stress agent. Regadenoson is a selective A\n                      <jats:sub>2A<\/jats:sub>\n                      adenosine receptor agonist used when MPI with exercise is contraindicated. It binds to the A\n                      <jats:sub>2A<\/jats:sub>\n                      receptor and stimulates adenylate cyclase, resulting in increased cAMP, which phosphorylates protein kinase A thereby opening the ATP-dependant potassium channels leading to hyperpolarization in the coronary vascular smooth muscle. After a single bolus dose of regadenoson 400 \u03bcg, a peak plasma concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ) of 13.6 ng\/mL is attained in 1-4 min, with a terminal half-life of 2 h. It has a quick onset, short duration sufficient enough for hyperemic response, with comparable efficacy to adenosine, but with fewer side-effects. The adverse effects of this drug are dyspnea, headache, flushing, chest pain and atrioventricular block. Regadenoson is used for MPI in patients with co-morbid conditions like mild-to-moderate reactive airway disease, obstructive lung disease and renal impairment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.97177","type":"journal-article","created":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T06:31:22Z","timestamp":1393223482000},"page":"140-146","source":"Crossref","is-referenced-by-count":11,"title":["Regadenoson"],"prefix":"10.4103","volume":"58","author":[{"given":"GM","family":"Bengalorkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Bhuvana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Sarala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TN","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20240205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/10489040-000000000-00000","article-title":"Regadenoson","volume":"10","author":"Garnock-Jones","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"R2-9-20240205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/VHRM.S1798","article-title":"Regadenoson in the detection of coronary artery disease","volume":"4","author":"Buhr","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"R3-9-20240205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/RMI.S3978","article-title":"Update on myocardial perfusion imaging: Role of regadenoson","volume":"2","author":"Hendel","year":"2009","journal-title":"Reports in Medical Imaging"},{"key":"R4-9-20240205","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","article-title":"Regadenoson: A new myocardial stress agent","volume":"54","author":"Jaroudi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R5-9-20240205","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1310\/hpj4401-57","article-title":"Regadenoson Injection","volume":"44","author":"Cada","year":"2009","journal-title":"Hosp Pharmacy"},{"key":"R7-9-20240205","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/S0960-894X(02)00609-1","article-title":"Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A 2A receptor","volume":"12","author":"Palle","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"R8-9-20240205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2967\/jnmt.108.057802","article-title":"Current methods of pharmacologic stress testing and the potential advantages of new agents","volume":"37","author":"Botvinick","year":"2009","journal-title":"J Nucl Med Technol"},{"key":"R9-9-20240205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-3-540-89615-9_6","article-title":"Adenosine receptors and the heart:Role in regulation of coronary blood flow and cardiac electrophysiology","volume":"193","author":"Mustafa","year":"2009","journal-title":"Hand B Exp Pharmacol"},{"key":"R10-9-20240205","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/cvr\/28.6.906","article-title":"ATP-sensitive potassium channels are involved in adenosine A 2 receptor mediated coronary vasodilatation in the dog","volume":"28","author":"Akatsuka","year":"1994","journal-title":"Cardiovasc Res"},{"key":"R11-9-20240205","doi-asserted-by":"crossref","first-page":"12441","DOI":"10.1073\/pnas.92.26.12441","article-title":"Adenosine activates ATP-sensitive potassium channels in arterial myocytes via A 2A receptors and cAMP-dependent protein kinase","volume":"92","author":"Kleppisch","year":"1995","journal-title":"Proc Natl Acad Sci"},{"key":"R12-9-20240205","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/01.CIR.98.7.711","article-title":"A 2A -adenosine receptor reserve for coronary vasodilation","volume":"98","author":"Shryock","year":"1998","journal-title":"Circulation"},{"key":"R13-9-20240205","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nuclcard.2007.02.016","article-title":"Regadenoson, a selective A 2A adenosine receptor agonist, causes dose-dependent increase in coronary blood flow velocity in humans","volume":"14","author":"Lieu","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"R14-9-20240205","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-3565(24)29370-8","article-title":"Novel short-acting A 2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A 2A agonists","volume":"298","author":"Gao","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-9-20240205","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jacc.2007.10.014","article-title":"Interaction of caffeine with regadenoson induced hyperemic myocardial blood flow as measured by positron emission tomography: A randomized, double-blind, placebo-controlled crossover trial","volume":"51","author":"Gaemperli","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R17-9-20240205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12350-008-9001-9","article-title":"The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist with low-level exercise, in patients undergoing myocardial perfusion imaging","volume":"16","author":"Thomas","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"R18-9-20240205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/RMI.S3978","article-title":"Update on myocardial perfusion imaging: Role of regadenoson","volume":"2","author":"Hendel","year":"2009","journal-title":"Rep Med Imaging"},{"key":"R19-9-20240205","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0091270007301620","article-title":"Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function","volume":"47","author":"Gordi","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R20-9-20240205","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.105.095323","article-title":"Tachycardia caused by A 2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats","volume":"316","author":"Dhalla","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R21-9-20240205","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ahj.2009.01.011","article-title":"Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus","volume":"157","author":"Hage","year":"2009","journal-title":"Am Heart J"},{"key":"R22-9-20240205","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2165\/00003088-200645120-00005","article-title":"A population pharmacokinetic\/pharmacodynamic analysis of regadenoson, an adenosine A 2A -receptor agonist, in healthy male volunteers","volume":"45","author":"Gordi","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R24-9-20240205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12350-010-9288-1","article-title":"Safety of regadenoson in patients with end-stage liver disease","volume":"18","author":"Al Jaroudi","year":"2011","journal-title":"J Nuc Cardiol"},{"key":"R25-9-20240205","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s12350-011-9399-3","article-title":"Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients","volume":"18","author":"Cavalcante","year":"2011","journal-title":"J Nuc Cardiol"},{"key":"R26-9-20240205","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12350-011-9378-8","article-title":"Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis","volume":"18","author":"Palani","year":"2011","journal-title":"J Nuc Cardiol"},{"key":"R27-9-20240205","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s00259-011-1853-6","article-title":"Comparison of the myocardial blood flow response to regadenoson and dipyridamole: A quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET","volume":"38","author":"Goudarzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-9-20240205","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/CIRCIMAGING.111.966341","article-title":"Rapid detection of coronary artery stenoses with real-time perfusion echocardiography during regadenoson stress","volume":"4","author":"Porter","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"key":"R29-9-20240205","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2005.05.097","article-title":"Initial clinical experience with regadenoson, a novel selective A 2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging","volume":"46","author":"Hendel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R30-9-20240205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2967\/jnmt.109.065581","article-title":"Advances in pharmacologic stress agents: Focus on regadenoson","volume":"38","author":"Johnson","year":"2010","journal-title":"J Nucl Med Technol"},{"key":"R32-9-20240205","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12350-009-9062-4","article-title":"Stress protocols and tracers. ASNC imaging guidelines for nuclear cardiology procedures","volume":"16","author":"Henzlova","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"R33-9-20240205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12350-011-9461-1","article-title":"Seizures associated with regadenoson: A case series","volume":"19","author":"Page","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"R34-9-20240205","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s12350-011-9373-0","article-title":"Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine","volume":"18","author":"Grady","year":"2011","journal-title":"J Nucl Cardiol"},{"key":"R37-9-20240205","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.seizure.2010.11.012","article-title":"Activation of central adenosine A 2A receptors lowers the seizure threshold of hyperthermia-induced seizure in childhood rats","volume":"20","author":"Fukuda","year":"2011","journal-title":"Seizure"},{"key":"R38-9-20240205","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. (ADVANCE MPI-2)","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"R39-9-20240205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","article-title":"Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A 2A agonist regadenoson versus adenosine in myocardial perfusion imaging. (Combined Analysis of ADVANCE MPI-1 and 2)","volume":"1","author":"Cerqueira","year":"2008","journal-title":"J Am Coll Cardiol Img"},{"key":"R40-9-20240205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nuclcard.2008.02.013","article-title":"Safety of regadenoson, a selective adenosine A 2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial)","volume":"15","author":"Thomas","year":"2008","journal-title":"J Nucl Cardiol"},{"key":"R41-9-20240205","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nuclcard.2008.02.009","article-title":"Safety of regadenoson, an adenosine A 2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial","volume":"15","author":"Leaker","year":"2008","journal-title":"J Nucl Cardiol"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201258020-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:46:00Z","timestamp":1787773560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201258020-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.97177","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}